BridgeBio Pharma has secured a $300 million upfront payment through a royalty financing agreement with HealthCare Royalty and Blue Owl Capital, which will bolster its financial position and support the launch of its drug Attruby® as well as ongoing late-stage programs. This deal allows BridgeBio to monetize 60% of its European royalties on the first $500 million of annual BEYONTTRA net sales, with total payments to investors capped at 1.45 times the original amount. Clinical trials for acoramidis, marketed as Attruby in the U.S. and BEYONTTRA in Europe, have shown promising results, including a 42% reduction in adverse cardiovascular events compared to placebo after 30 months. The funding aims to enhance the company’s ability to develop innovative genetic therapies while preserving shareholder value.
